Elite in Pulmonary Hypertension

Dr. Veronica Franco

Advanced Heart Failure and Transplant Cardiology | Cardiology
Osu Internal Medicine LLC
920 N Hamilton Rd, 
Gahanna, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Elite in Pulmonary Hypertension
Osu Internal Medicine LLC
920 N Hamilton Rd, 
Gahanna, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Veronica Franco is an Advanced Heart Failure and Transplant Cardiologist and a Cardiologist in Gahanna, Ohio. Dr. Franco is rated as an Elite provider by MediFind in the treatment of Pulmonary Hypertension. Her top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Heart Failure with Preserved Ejection Fraction (HFpEF), Heart Transplant, and Cardiac Ablation. Dr. Franco is currently accepting new patients.

Her clinical research consists of co-authoring 24 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 11 articles and participated in 13 clinical trials in the study of Pulmonary Hypertension.

Specialties
Advanced Heart Failure and Transplant Cardiology
Cardiology
Licenses
Internal Medicine in OH
Hospital Affiliations
Ohio State University State Health System
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

OSU INTERNAL MEDICINE LLC
920 N Hamilton Rd, Gahanna, OH 43230

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

RELIEVE-PAH TRIAL: REducing Right ventricuLar faIlure With thE V-waVe Shunt in Pulmonary Arterial Hypertension
RELIEVE-PAH TRIAL: REducing Right ventricuLar faIlure With thE V-waVe Shunt in Pulmonary Arterial Hypertension
Enrollment Status: Recruiting
Publish Date: June 07, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Phase 2b, Open-label, Single Dose Study to Evaluate the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects With Pulmonary Arterial Hypertension (PAH)
A Phase 2b, Open-label, Single Dose Study to Evaluate the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects With Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Completed
Publish Date: September 18, 2025
Intervention Type: Combination product
Study Drug: RT234
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Enrollment Status: Terminated
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 07, 2023
Intervention Type: Drug
Study Drug: Intravenous/Subcutaneous Treprostinil
Study Phase: Phase 4
Dietary Supplementation in Heart Failure
Dietary Supplementation in Heart Failure
Enrollment Status: Completed
Publish Date: October 22, 2021
Intervention Type: Dietary supplement
Study Phase: Not Applicable
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Dose Titration Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046, A Sustained-Release Analogue of Vasoactive Intestinal Peptide, In Adult Subjects With Pulmonary Arterial Hypertension
An Open-Label, Dose Titration Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046, A Sustained-Release Analogue of Vasoactive Intestinal Peptide, In Adult Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: October 08, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 13 Less Clinical Trials

24 Total Publications

Sotatercept Use in a Patient with Pulmonary Arterial Hypertension Undergoing Lung Transplantation.
Sotatercept Use in a Patient with Pulmonary Arterial Hypertension Undergoing Lung Transplantation.
Journal: JHLT open
Published: March 27, 2025
Similar Doctors
Elite in Pulmonary Hypertension
Dr. Scott H. Visovatti
Cardiology
Elite in Pulmonary Hypertension
Dr. Scott H. Visovatti
Cardiology

Osu Internal Medicine LLC

452 W 10th Ave, 
Columbus, OH 
 (8.8 miles away)
614-293-3737
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Visovatti is a Cardiologist in Columbus, Ohio. Dr. Visovatti is rated as a Distinguished provider by MediFind in the treatment of Pulmonary Hypertension. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Systemic Sclerosis (SSc), Hypertension, and Angioplasty. Dr. Visovatti is currently accepting new patients.

Advanced in Pulmonary Hypertension
Dr. Lindsay M. Castle
Advanced Heart Failure and Transplant Cardiology | Cardiology
Advanced in Pulmonary Hypertension
Dr. Lindsay M. Castle
Advanced Heart Failure and Transplant Cardiology | Cardiology

Ohiohealth Corporation

3525 Olentangy River Rd, Suite 6300, 
Columbus, OH 
 (8.9 miles away)
614-566-3175
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lindsay Castle is an Advanced Heart Failure and Transplant Cardiologist and a Cardiologist in Columbus, Ohio. Dr. Castle is rated as a Distinguished provider by MediFind in the treatment of Pulmonary Hypertension. Her top areas of expertise are Heart Failure, Pulmonary Edema, Heart Failure with Preserved Ejection Fraction (HFpEF), Cardiac Ablation, and Pacemaker Implantation. Dr. Castle is currently accepting new patients.

Distinguished in Pulmonary Hypertension
Dr. Manmohan K. Katapadi
Cardiology | Nuclear Medicine
Distinguished in Pulmonary Hypertension
Dr. Manmohan K. Katapadi
Cardiology | Nuclear Medicine

Ohio Heart Group, Inc.

800 E Broad St, 
Columbus, OH 
 (8.0 miles away)
614-252-8300
Languages Spoken:
English, Georgian, Hindi, Kannada
See accepted insurances
Accepting New Patients

Manmohan Katapadi is a Cardiologist and a Nuclear Medicine provider in Columbus, Ohio. Dr. Katapadi is rated as a Distinguished provider by MediFind in the treatment of Pulmonary Hypertension. His top areas of expertise are Heart Failure, Pulmonary Edema, Heart Failure with Preserved Ejection Fraction (HFpEF), and Mitral Valve Prolapse. Dr. Katapadi is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Franco's expertise for a condition
ConditionClose
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile